The mean PCSK9 concentrations did not differ between patients with and without NAFLD, smokers vs. nonsmokers, on statin therapy vs. nonstatin takers, nor with or without CAD. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.